← Eichor
Study identifier: NCT07325721 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

Condition: Prostate Cancer · Prostate Cancer Patients Treated by Radiotherapy  ·  Sponsor: Medical University of South Carolina

PhasePhase 2
Planned participants46
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two emerging radiation treatment techniques (hypofractionated radiotherapy and microboost technique). Participation will include standard of care visits along with questionnaires and blood draws completed for research purposes. There is optional banking of blood and prostate biopsy tissue which will not require extra biopsies. Participation in this study is anticipated to last approximately 6 weeks with follow up every three months for two years then twice yearly for years 3-5.

This description comes directly from the study's public registry record.

Talk to the study team

Harriet Eldredge-Hindy Eldredge-Hindy, MD  ·  8437926382  ·  eldredge@musc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Medical University of South Carolina Hollings Cancer CenterCharleston, South Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07325721